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60 Ceftazidime shows concentration-dependent killing on
b-lactamase-overproducing bioﬁlm of Pseudomonas aeruginosa
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Background: Resistance to ceftazidime due to hyper-production of chromosomally
encoded b-lactamase is frequently encountered in P. aeruginosa isolates from
patients with cystic ﬁbrosis and chronic lung infections.
Aims: The purpose of this study was to investigate the role of b-lactamase in the
pharmacokinetics and pharmacodynamics of ceftazidime on P. aeruginosa bioﬁlms.
Methods: Pseudomonas aeruginosa PAO1 (7.8U, Nitroceﬁn hydrolysed/min /mg
protein) and its overproducing b-lactamase mutant PADDDh2Dh3 (10933.7U) were
used in this study. Bioﬁlms of these two strains in ﬂow-cells, microtiter-plate, and
alginate beads were treated with different concentrations of ceftazidime (0.125 to
1024mg/ml) and the killing effect was investigated. Colistin was used as a control
antibiotic which effect is not affected by b-lactamase.
Results: Time-dependent killing of ceftazidime was observed in the P. aeruginosa
PAO1 bioﬁlms, but concentration-dependent killing activity was observed for
b-lactamase-overproducing bioﬁlms of P. aeruginosa in all the three models in vitro.
Colistin showed concentration-dependent killing on both PAO1 and PADDDh2Dh3
bioﬁlms.
Conclusions: The PK/PD indices of AUC/MBIC and Cmax /MBIC (AUC, area
under curve; Cmax, maximum concentration; MBIC, minimal bioﬁlm inhibitory
concentration) are probably best to describe the effect of ceftazidime in b-lactamase-
overproducing bioﬁlms P. aeruginosa. This is probably due to the special distribu-
tion and accumulation of b-lactamase in the bioﬁlm matrix which can hydrolyze
the b-lactam antibiotics. The study will probably be useful to optimize the dosage
regimens of b-lactam antibiotics for CF patients.
61 Colistin efﬁcacy for children with cystic ﬁbrosis (CF) at the ﬁrst
isolation of Pseudomonas aeruginosa (PA)
V. Nikonova1, N. Kapranov1. 1Research Center Medical Genetic of Russian
Academy of Science, Moscow, Russian Federation
Objective: To estimate efﬁciency of Colistin for children with CF with the ﬁrst
isolation of PA in different age groups.
Material: 30 patients with ﬁrst isolation of PA aged from 0.2 to 15.8 years, the
average age of patients was 5.4 (±4.9) years. A group of 19 children from 0 to
6 years (2.2±1.6), 2 groups of 11 children from 6 to 16 years (10.8±3.9). Colistin
was administered at the dose of 0.5−2 million twice a day in addition to standard
therapy of CF and oral ciproﬂoxacin 30mg/kg/day during 21 days. Criterion of
efﬁciency: microbiological of the sputum, spirometry (FEV1, FVC in the second
group), nutritional status.
Conclusions: The eradication of PA 1 group − 11%, 2 group − 18%, increase in
FEV1-7.4% (p = 0.001), FVC 5.5% (p = 0.004). Increase in BMI in the 1 group −
0.7% (p = 0.001), in the 2 − 0.4% (p = 0.001). Colistin is effective for eradication
of PA in all age groups and is recommended for children with ﬁrst isolate.
62 The use of trimethoprim suspension for anti-staphylococcal
prophylaxis (ASP) in children with cystic ﬁbrosis; the importance
of a palatable preparation
E. Lewis1, K.E. Brennan1, K.W. Southern2. 1University of Liverpool, Liverpool,
United Kingdom; 2Alder Hey Children’s Hospital Foundation Trust, Liverpool,
United Kingdom
Background: Maintaining long-term antibiotic treatment in children who cannot
take capsules requires a palatable suspension. When cefradine (velosef™) was taken
off the market, we examined alternative preparations. We were keen not to use
cefalexin due to adverse trial data suggesting increased Pseudomonas infection.
With ﬂoxapen™ unavailable, we found ﬂucloxacillin preparations unacceptable.
We opted for trimethoprim suspension (commonly used in paediatrics for long-
term therapy, with a unique spectrum of action).
Methods: We assessed the acceptability of trimethoprim suspension following
the changeover (autumn 2010). We also assessed microbiology in children on
trimethoprim, compared to an equivalent time period before the change.
Results: 27 children under the age of 6 were included. 6 children were commenced
on capsules and did not require trimethoprim. Whilst on trimethoprim: 1 child did
not tolerate it; 1 child had repeated Staphylococcus aureus (SA) growths; and 1
child grew MRSA several times. 1 child was switched to capsules after a short
period. In the remaining 16 children, there were no growths of SA following the
change to trimethoprim and less overall bacterial growth compared to the same time
period before the switch.
Discussion: Overall trimethoprim suspension was well tolerated. Repeated SA and
MRSA growths in 2 patients are a concern. There is no deﬁned CF dose for
trimethoprim; we used the standard dose in the BNF for children. Long term ASP
is a challenge and palatable suspensions are essential in young children. These data
suggest trimethoprim may offer an option in this age group but larger studies are
required.
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Objectives: Recent reports point to Achromobacter xylosoxidans as an emerging
pathogen in cystic ﬁbrosis (CF). While antimicrobial therapy has been shown to
postpone the establishment of chronic infection for other bacteria, this needs to be
explored for A. xylosoxidans.
Methods: Excluding documented cross-infections with an epidemic strain of Achro-
mobacter, thirty-eight patients experienced a ﬁrst-time detection of A. xylosoxidans
at the two Danish CF centres during 2000−11. Using a Kaplan Meier estimation,
the median time to recurrence was 7.5 months.
Results: Thirty-two ﬁrst-time isolates of A. xylosoxidans were preserved, and
the minimal inhibitory concentration (MIC) of 14 antibiotics was determined by
Etest®. According to EUCAST guidelines, 94% of the isolates were susceptible to
piperacillin-tazobactam (MIC90 = 6mg/L), 88% to meropenem (MIC90 = 2mg/L),
73% to colistin (MIC90 = 8mg/L), 23% to ceftazidime (MIC90 = 24mg/L), and
9% to tobramycin (MIC90 = 96mg/L). MIC90 for trimethoprim-sulfamethoxazole
was 0.047mg/L, however interpretative criteria have not been established.
Nineteen patients received intravenous treatment with piperacillin-tazobactam or
meropenem, or oral treatment with trimethoprim-sulfamethoxazole, for at least
14 days after the ﬁrst isolation of A. xylosoxidans, and these patients had a median
time to recurrence of 13.5 months. For the nineteen patients who did not receive
any of these regimens, the median time to recurrence was 4.5 months.
Conclusion: Antibiotic treatment of primary A. xylosoxidans colonisation may
postpone time to recurrence and establishment of chronic infection in cystic ﬁbrosis.
